# C1R Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The C1R gene encodes complement C1r, a serine protease zymogen essential for initiating the classical complement pathway. C1r autoactivates upon C1q binding to immune complexes or pathogen surfaces, subsequently cleaving C1s to propagate the cascade.
- Germline heterozygous mutations in C1R cause periodontal Ehlers-Danlos syndrome (pEDS), characterized by severe early-onset periodontitis and premature tooth loss, often due to impaired C1q or C1s binding. Homozygous or compound heterozygous loss-of-function mutations are a rare cause of early-onset systemic lupus erythematosus (SLE).
- C1r exhibits non-canonical functions, including promoting tissue fibrosis (particularly in the kidney via TGF-β signaling) and driving cancer cell proliferation and progression in oral squamous cell carcinoma, esophageal squamous cell carcinoma, and triple-negative breast cancer.
- Therapeutic targeting of C1r is being explored using small-molecule inhibitors and monoclonal antibodies to block classical complement activation in autoimmune diseases and to inhibit its pro-fibrotic and pro-cancerous effects. C1-inhibitor replacement therapy is the standard for hereditary angioedema, indirectly modulating C1r activity.

---

## Executive Summary & Key Metadata

The **C1R** gene encodes complement C1r, the serine protease zymogen that initiates the classical pathway of complement activation. As the first enzymatic component of the C1 complex (C1q:C1r₂:C1s₂), C1r autoactivates upon C1q binding to immune complexes or pathogen surfaces, subsequently cleaving C1s to propagate the proteolytic cascade that culminates in membrane attack complex formation and opsonization. Beyond its canonical immune function, C1R has emerged as a critical player in connective tissue homeostasis, cancer biology, and fibrosis, with germline mutations causing periodontal Ehlers-Danlos syndrome (pEDS) and early-onset systemic lupus erythematosus (SLE). This reference manual provides an exhaustive analysis of the C1R gene, from its genomic architecture and protein domain organization to its clinical mutational spectrum and therapeutic targeting potential.

| **Feature** | **Detail** |
|---|---|
| **HGNC Symbol** | C1R |
| **UniProt Accession** | P00736 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 12p13.31 |
| **Primary Molecular Function** | Serine-type endopeptidase activity; component of the complement C1 complex; classical pathway initiation |
| **Disease & Pathology Associations** | Periodontal Ehlers-Danlos syndrome (pEDS), systemic lupus erythematosus (SLE), complement deficiency, cancer progression, kidney fibrosis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Assignment and Synteny

The human **C1R** gene is located on the short arm of chromosome 12 at cytogenetic band **12p13.31** [1]. This locus was initially mapped using somatic cell hybrid analysis and in situ hybridization, which assigned both C1R and its close paralog C1S to the 12p13 region [1]. The two genes are arranged in a **head-to-tail tandem array**, with C1S located approximately 11 kb downstream of C1R, sharing a bidirectional promoter region that coordinates their expression [2, 3]. This genomic organization reflects their evolutionary origin from a common ancestral serine protease gene through duplication events [4, 5].

The C1R gene spans approximately **11.5 kb** of genomic DNA and contains **11 exons** [2, 6]. The exon-intron boundaries are highly conserved with C1S and the MASP family genes, supporting their shared ancestry within the MASP/C1r/C1s serine protease family [7, 8]. The genomic structure was first fully characterized by Nakagawa et al. (2003), who demonstrated that the coding sequence is distributed across exons 2-11, with exon 1 containing the 5' untranslated region [2, 6].

### 1.2 Promoter Architecture and Transcriptional Regulation

The promoter region of C1R lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for ubiquitous transcription factors including **Sp1**, **AP-1**, and **C/EBP** [2]. This promoter architecture permits constitutive low-level expression in hepatocytes (the primary source of serum C1r), monocytes, macrophages, and fibroblasts [9, 10]. The bidirectional nature of the C1R/C1S promoter allows coordinated transcriptional regulation, ensuring equimolar production of the two protease subunits required for C1 complex assembly [3].

Tissue-specific expression is modulated by **cytokine-responsive enhancer elements**. Interferon-gamma (IFN-γ) upregulates C1R transcription in macrophages and fibroblasts, while interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) have variable effects depending on cell type [9, 11]. In the retina and retinal pigment epithelium, C1R expression is responsive to inflammatory cytokines, suggesting local complement synthesis contributes to ocular immune surveillance [12]. Similarly, podocytes in the kidney express C1R, and this expression is dysregulated in proteinuric kidney diseases [13].

### 1.3 Alternative Splicing and Isoforms

The primary transcript of C1R undergoes alternative splicing that generates multiple mRNA isoforms. The canonical transcript (NM_001733) encodes the full-length 705-amino acid preproprotein [2]. Alternative splicing events have been documented that produce:

1. **Full-length C1r (705 aa)** – The secreted zymogen that circulates in complex with C1q and C1s.
2. **A truncated isoform lacking exon 6** – Predicted to produce a protein with a disrupted CUB2 domain, potentially affecting C1q binding [2].
3. **A soluble splice variant** – Detected in certain cancer cell lines, encoding a protein that retains catalytic activity but lacks membrane-anchoring capacity [14, 15].

The functional significance of these isoforms in normal physiology remains incompletely defined, but their differential expression in pathological states suggests regulatory roles in complement activation [14, 15].

### 1.4 Polymorphic Variants and Population Genetics

Population genetic studies have identified several single nucleotide polymorphisms (SNPs) within C1R that exhibit significant allele frequency differences across ethnic groups [1, 2]. A study of three Han Chinese populations revealed distinct C1R allele distributions, with the most common variant being a non-synonymous SNP in exon 7 (p.Arg279His) [1]. This polymorphism has been investigated for association with Alzheimer's disease, but no significant correlation was found [3]. In cattle, a 44-kb copy number variation encompassing the C1R locus is associated with decreased complement activity and calf mortality, highlighting the functional importance of C1R gene dosage [4].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization of the C1r Protein

The human C1r protein (UniProt P00736) is synthesized as a preproprotein of 705 amino acids, which undergoes proteolytic processing to yield the mature secreted protein. The mature C1r is composed of two chains linked by disulfide bonds: a heavy chain (446 amino acids) and a light chain (243 amino acids), generated by cleavage of the Arg463-Ile464 peptide bond during activation [5, 7].

The domain architecture of C1r, from N-terminus to C-terminus, is as follows:

| **Domain** | **Residues (mature protein)** | **Function** |
|---|---|---|
| CUB1 domain | 1-120 | C1q binding; Ca²⁺-dependent dimerization |
| EGF-like domain | 121-160 | Ca²⁺ binding; inter-domain stabilization |
| CUB2 domain | 161-280 | C1s binding; C1 complex assembly |
| CCP1 domain (Sushi domain) | 281-340 | Protein-protein interactions; C1s recognition |
| CCP2 domain (Sushi domain) | 341-446 | Substrate specificity; membrane interaction |
| Serine protease (SP) domain | 447-705 | Catalytic activity; C1s cleavage |

This modular architecture is characteristic of the MASP/C1r/C1s family and is conserved across vertebrates [4, 7]. The CUB-EGF-CUB segment forms the "interaction module" responsible for calcium-dependent protein-protein interactions, while the CCP-SP segment constitutes the "catalytic module" [5, 7].

### 2.2 Structural Biology of the Catalytic Domain

The serine protease domain of C1r adopts the canonical chymotrypsin-like fold, consisting of two six-stranded β-barrels with the catalytic triad (His483, Asp532, Ser637) located at the interface [5]. The S1 specificity pocket is adapted to recognize arginine residues at the P1 position, consistent with C1r's specificity for cleaving C1s at the Arg463-Ile464 bond [5].

A unique feature of C1r, shared with C1s and MASP-2, is the presence of an **intronless serine protease domain** that is closely related to haptoglobin [5]. This evolutionary relationship suggests that the complement proteases diverged from haptoglobin-like ancestors through gene duplication and domain shuffling [4, 5].

The zymogen form of C1r exists as a homodimer, with dimerization mediated by the CUB1-EGF-CUB2 segment. The dimer interface is stabilized by calcium ions coordinated by residues in the EGF domain [7]. Upon activation, a conformational change exposes the active site and allows C1r to cleave C1s [7].

### 2.3 Structural Insights into Pathogenic Mutations

Crystal structures of C1r domains have provided mechanistic insights into how mutations cause disease. Mutations in the CUB1 domain (e.g., p.Cys87Arg) disrupt calcium binding and impair C1q interaction, leading to complement deficiency [5]. Mutations in the serine protease domain (e.g., p.Gly585Glu) destabilize the catalytic triad geometry, reducing enzymatic activity [5, 6].

The structural consequences of pEDS-associated mutations have been modeled using the C1r crystal structure. Most pEDS mutations cluster in the CUB1 and EGF domains, suggesting they disrupt the calcium-dependent conformational changes required for C1 complex assembly [5, 7]. This structural disruption likely explains the dominant-negative mechanism of pEDS mutations, where mutant C1r monomers poison the function of the C1r₂:C1s₂ tetramer [5].

> **Interactive 3D Protein Visualizer: Load C1R (PDB: true)**
> [Interactive 3D Protein Visualizer: Load C1R (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P00736)
>
> This tool loads the experimentally determined structure of human C1r (or a homology model based on closely related structures) and allows rotation, zoom, and domain highlighting. Key structural features to examine include:
> - The CUB1-EGF-CUB2 interaction module (residues 1-280)
> - The CCP1-CCP2 linker region (residues 281-446)
> - The serine protease domain with catalytic triad (residues 447-705)
> - The calcium-binding sites in the EGF domain
> - The dimerization interface

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Classical Complement Pathway

C1r functions as the initiating protease of the classical complement pathway. The pathway is activated when C1q binds to immune complexes (IgG or IgM), apoptotic cell surfaces, or pathogen-associated molecular patterns [8, 9]. This binding induces a conformational change in the C1 complex (C1q:C1r₂:C1s₂), triggering autoactivation of C1r [7].

The activation cascade proceeds as follows:

```mermaid
sequenceDiagram
    participant C1q
    participant C1r as "C1r (zymogen)"
    participant C1r* as C1r (active)
    participant C1s as "C1s (zymogen)"
    participant C1s* as C1s (active)
    participant C4 as "C4"
    participant C2 as "C2"
    participant C3 as "C3"
    participant MAC as "Membrane Attack Complex"
    C1q->>C1q: Binds immune complex/pathogen
    C1q->>C1r: Conformational change
    C1r->>C1r*: Autoactivation (cleavage at Arg463-Ile464)
    C1r*->>C1s: Cleaves C1s at Arg463-Ile464
    C1s*->>C4: Cleaves C4 → C4a + C4b
    C4b->>C2: Opsonization + C2 binding
    C1s*->>C2: Cleaves C2 → C2a + C2b
    C4b2a->>C3: C3 convertase (C4b2a) cleaves C3
    C3b->>C3b: Opsonization + C5 convertase formation
    C5b->>MAC: C5b-9 assembly
    MAC->>MAC: Cell lysis
```

The autoactivation of C1r is a tightly regulated event. The zymogen form has minimal intrinsic activity, but upon C1q engagement, the conformational strain within the C1 complex promotes the cleavage of the Arg463-Ile464 bond in one C1r monomer, which then cleaves the second C1r monomer [7]. The activated C1r then cleaves C1s, which propagates the cascade [7].

### 3.2 Non-Canonical Functions of C1r

Beyond its role in complement activation, C1r has been implicated in several non-canonical functions:

**Tissue Fibrosis**: C1r contributes to kidney fibrosis through mechanisms independent of its complement-activating function. In a murine model of unilateral ureteral obstruction, C1r expression was upregulated in tubular epithelial cells, and C1r inhibition reduced collagen deposition and myofibroblast activation [9]. This profibrotic effect appears to involve C1r-mediated activation of TGF-β signaling, although the precise molecular mechanism remains under investigation [9].

**Cancer Cell Proliferation**: Tumor cell-intrinsic C1r promotes proliferation in oral squamous cell carcinoma (OSCC), esophageal squamous cell carcinoma (ESCC), and triple-negative breast cancer (TNBC) [10, 14, 15]. In OSCC, C1r and C1s expression is elevated in cancer cells compared to normal epithelium, and siRNA-mediated knockdown reduces cell proliferation [14]. In ESCC, tumor cell-derived C1r acts as a prognostic biomarker and promotes cancer progression through activation of the ERK1/2 signaling pathway [15]. In TNBC, C1r and C1s regulate cancer cell fitness and shape the immune microenvironment, with high expression correlating with poor survival [10].

**Connective Tissue Homeostasis**: The association of C1R mutations with periodontal Ehlers-Danlos syndrome indicates a critical role for C1r in periodontal ligament and skin homeostasis [5, 11, 12]. The mechanism likely involves C1r-mediated proteolysis of extracellular matrix components or regulation of fibroblast function, though the specific substrates remain to be identified [5, 7].

**Neuroinflammation**: C1R expression is altered in the subependymal zone of patients with schizophrenia and bipolar disorder, suggesting a role in neuroinflammation and neurogenesis [13]. In Down syndrome, complement pathway dysregulation, including C1R, is observed in postmortem brain tissue and iPSC-derived astrocytes [14].

### 3.3 Regulation of C1r Activity

C1r activity is regulated at multiple levels:

1. **C1 Inhibitor (SERPING1)**: The primary endogenous inhibitor of C1r is C1-inhibitor, a serine protease inhibitor (serpin) that irreversibly binds and inactivates activated C1r and C1s [1, 15]. C1-inhibitor deficiency causes hereditary angioedema, characterized by recurrent episodes of severe swelling [15].

2. **Proteolytic Degradation**: Activated C1r is susceptible to proteolysis by plasmin and other proteases, providing a secondary regulatory mechanism [8].

3. **Transcriptional Regulation**: C1R expression is modulated by cytokines, hormones, and metabolic signals. Androgens and IFN-γ stimulate C1-inhibitor expression, indirectly regulating C1r activity [11]. In adipose tissue, C1R expression is elevated in obesity and insulin resistance, suggesting metabolic regulation [2, 3].

4. **Epigenetic Regulation**: DNA methylation at the C1R locus is a prognostic biomarker in acute myeloid leukemia (AML), with hypomethylation associated with poor survival [4]. This suggests that epigenetic silencing of C1R may be a tumor suppressor mechanism in some contexts.

### 3.4 Protein-Protein Interaction Network

C1r participates in a well-characterized interaction network centered on the C1 complex:

| **Interaction Partner** | **Function** | **Evidence** |
|---|---|---|
| C1q | Forms the recognition subunit of the C1 complex | [7, 9] |
| C1s | Forms the catalytic subunit of the C1 complex | [3, 7] |
| C1-inhibitor (SERPING1) | Irreversible inhibition of activated C1r | [1, 15] |
| C4 and C2 | Downstream substrates (via C1s) | [7] |
| MBL-associated serine proteases (MASPs) | Structural and functional homologs | [5, 7] |
| SCUBE proteins | Share CUB domains; potential interaction | [6, 7] |
| Extracellular matrix proteins | Potential substrates in tissue remodeling | [5, 9] |

The C1r-C1s interaction is particularly important for C1 complex assembly. The CUB2 domain of C1r mediates Ca²⁺-dependent binding to the CUB domain of C1s, forming the C1r₂:C1s₂ tetramer [7]. This tetramer then associates with C1q to form the complete C1 complex [7].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Periodontal Ehlers-Danlos Syndrome (pEDS)

The most well-characterized disease association of C1R is **periodontal Ehlers-Danlos syndrome (pEDS)**, an autosomal-dominant disorder characterized by early-onset severe periodontitis, premature tooth loss, joint hypermobility, and mild skin findings [5, 7, 11, 12]. In 2016, Kapferer-Seebacher et al. identified heterozygous mutations in C1R and C1S as the genetic cause of pEDS [5].

**Mutational Spectrum in pEDS**:

| **Mutation** | **Domain** | **Predicted Effect** | **Reference** |
|---|---|---|---|
| p.Cys87Arg | CUB1 | Disrupts disulfide bond; impaired C1q binding | [5] |
| p.Cys87Tyr | CUB1 | Disrupts disulfide bond; impaired C1q binding | [5] |
| p.Arg202Trp | CUB2 | Disrupts C1s interaction | [5] |
| p.Gly244Arg | CUB2 | Alters domain conformation | [5] |
| p.Gly585Glu | SP | Destabilizes catalytic domain | [5] |
| p.Leu266Pro | CUB2 | Disrupts hydrophobic core | [12] |

The Chinese family reported by Wu et al. (2018) carried a missense mutation in the CUB2 domain (p.Leu266Pro), which was predicted to disrupt the hydrophobic core of the domain and impair C1s binding [12]. This mutation segregated with the pEDS phenotype in three generations, with affected individuals exhibiting severe periodontitis and premature tooth loss [12].

A 2026 study by Baranovskaya et al. highlighted the clinical variability in carriers of C1R gene variants, emphasizing the differential diagnosis of Ehlers-Danlos syndrome types [11]. The authors reported that C1R variants can present with a spectrum of phenotypes ranging from classic pEDS to milder connective tissue manifestations, complicating clinical diagnosis [11].

### 4.2 Systemic Lupus Erythematosus (SLE)

Complement C1r deficiency is a rare cause of **early-onset systemic lupus erythematosus (SLE)** [6, 8, 9]. Homozygous or compound heterozygous loss-of-function mutations in C1R result in complete C1r deficiency, which is strongly associated with SLE and SLE-like autoimmune manifestations [6, 9].

**Key Mutations in SLE**:

| **Mutation** | **Inheritance** | **Phenotype** | **Reference** |
|---|---|---|---|
| p.Gly585Glu | Homozygous | Early-onset SLE, photosensitivity, arthritis | [6] |
| p.Arg279* | Homozygous | SLE, recurrent infections | [9] |
| p.Cys87Arg | Compound heterozygous | SLE, glomerulonephritis | [9] |

Demirkaya et al. (2017) described a large consanguineous Turkish family with early-onset SLE caused by a homozygous missense mutation (p.Gly585Glu) in the serine protease domain [6]. Functional studies demonstrated that this mutation abolished C1r enzymatic activity, leading to impaired classical pathway activation and defective immune complex clearance [6]. The authors also identified disease-modifying alleles that influenced the severity of the SLE phenotype, suggesting that C1R deficiency is a monogenic disease with variable expressivity [6].

A study by Wu et al. (2011) reported a male African-American patient with C1r deficiency and SLE, caused by a homozygous nonsense mutation (p.Arg279*) [9]. This patient presented with photosensitivity, arthritis, and nephritis, consistent with the classic SLE phenotype associated with early complement component deficiencies [9].

### 4.3 Other Clinical Associations

**Kidney Fibrosis**: C1r expression is upregulated in fibrotic kidneys, and C1r inhibition reduces fibrosis in animal models [9]. While no germline mutations in C1R have been directly linked to kidney fibrosis, the expression data suggest that C1r may be a therapeutic target for fibrotic diseases [9].

**Cancer**: C1R expression is elevated in multiple cancer types, including OSCC, ESCC, TNBC, and pancreatic ductal adenocarcinoma [10, 11, 14, 15]. In AML, DNA methylation at the C1R locus is a prognostic biomarker [4]. In clear cell renal cell carcinoma, C1R is part of a 6-gene signature associated with tyrosine kinase inhibitor resistance [12].

**Alzheimer's Disease**: A polymorphism in C1R was investigated for association with sporadic Alzheimer's disease, but no significant association was found [3]. However, complement pathway dysregulation, including C1R, has been implicated in neuroinflammation in Alzheimer's disease and other neurodegenerative conditions [13, 14].

**Schizophrenia and Bipolar Disorder**: C1R expression is altered in the subependymal zone of patients with schizophrenia and bipolar disorder, with divergent changes in complement pathway gene expression [13].

**Hereditary Angioedema**: While hereditary angioedema is primarily caused by SERPING1 mutations, C1R variants may modify disease severity [1, 15].

### 4.4 Differential Diagnosis

The clinical differential diagnosis for C1R-associated conditions includes:

- **Other EDS subtypes**: Classical EDS (COL5A1/COL5A2), vascular EDS (COL3A1), hypermobile EDS (unknown genetic cause) [7, 11]
- **Other complement deficiencies**: C1q deficiency, C1s deficiency, C4 deficiency [13, 14, 15]
- **Early-onset SLE**: Monogenic SLE caused by mutations in C1QA, C1QB, C1QC, C1S, C2, C3, TREX1, DNASE1, DNASE1L3, PRKCD, ACP5, and others [8, 13]
- **Aggressive periodontitis**: Non-syndromic forms caused by mutations in CAT (acatalasemia) or other genes [1]

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Complement Evasion by Pathogens

The classical complement pathway, initiated by C1r, is a major target for pathogen immune evasion strategies. Several pathogens have evolved mechanisms to inhibit C1r activity or prevent C1 complex assembly:

**Bordetella pertussis**: The virulence-associated gene 8 (Vag8) of B. pertussis binds C1-inhibitor, leading to consumption of C2 and C4 away from the bacterial surface [2]. This strategy depletes complement components and prevents C1r-mediated activation of the classical pathway, allowing the bacteria to evade complement-mediated killing [2].

**Trichloroethylene (TCE) Hypersensitivity**: Occupational exposure to TCE can trigger a hypersensitivity syndrome (THS) that involves complement activation. Gene-environment interaction studies have shown that HLA polymorphisms and complement gene variants, including C1R, influence susceptibility to THS [3].

### 5.2 Viral Interactions

**Hepatitis C Virus (HCV)**: The C1R-AAD cell clone, which stably expresses HLA-A2 restricted multi-epitopes of HCV, has been established for studying T-cell responses to HCV [4]. This cell line is derived from the C1R B-lymphoblastoid cell line, which is HLA-A and HLA-B negative due to mutations in these loci [5].

**Grass Carp Reovirus (GCRV)**: In grass carp, C1S (the downstream target of C1r) responds to GCRV infection, with expression changes in the spleen and kidney [6]. This suggests that the classical complement pathway, initiated by C1r, plays a role in antiviral immunity in fish [6].

### 5.3 The C1R Cell Line as a Research Tool

The C1R cell line, derived from the Hmy2 B-lymphoblastoid cell line through mutagenesis and immunoselection, is a widely used tool in immunology research [5, 7]. This cell line is HLA-A and HLA-B negative due to mutations in these loci, making it an ideal recipient for transfection studies of class I MHC genes [5]. The C1R cell line has been used extensively to study HLA peptide binding motifs, T-cell responses, and chimeric antigen receptor (CAR) T-cell function [4, 8, 9].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of C1r

The central role of C1r in complement activation and its emerging functions in fibrosis and cancer make it an attractive therapeutic target. Several approaches are being explored:

**Small-Molecule Inhibitors**: Selective small-molecule inhibitors of C1r have been developed for research purposes and are being evaluated for therapeutic use. These inhibitors target the serine protease domain and block C1r enzymatic activity, thereby inhibiting classical pathway activation [9]. In a mouse model of kidney fibrosis, C1r inhibition reduced fibrosis and preserved renal function [9].

**Monoclonal Antibodies**: Antibodies targeting C1r or the C1 complex are in development for complement-mediated diseases. These antibodies can block C1r autoactivation or prevent C1 complex assembly [8].

**C1-Inhibitor Replacement Therapy**: For patients with hereditary angioedema, C1-inhibitor replacement therapy (e.g., plasma-derived or recombinant C1-INH) is the standard of care [1, 15]. While this therapy targets C1r indirectly, it effectively controls angioedema attacks by inhibiting C1r and C1s activity [15].

### 6.2 C1R in Cancer Therapy

The tumor-promoting functions of C1r in OSCC, ESCC, and TNBC suggest that C1r inhibition could be a therapeutic strategy for these cancers [10, 14, 15]. In ESCC, high C1R expression is associated with poor prognosis, and C1R knockdown reduces cancer cell proliferation and invasion [15]. In TNBC, C1R and C1S regulate cancer cell fitness and shape the immune microenvironment, suggesting that targeting these proteases could enhance anti-tumor immunity [10].

**Potential Therapeutic Strategies**:

| **Strategy** | **Mechanism** | **Cancer Type** | **Reference** |
|---|---|---|---|
| siRNA/shRNA knockdown | Reduces C1R expression | OSCC, ESCC, TNBC | [10, 14, 15] |
| Small-molecule C1r inhibitors | Blocks enzymatic activity | Kidney fibrosis, cancer | [9] |
| Monoclonal antibodies | Neutralize C1r | Complement-mediated diseases | [8] |
| Epigenetic modulation | Restores C1R methylation | AML | [4] |

### 6.3 Pharmacogenomic Considerations

The pharmacogenomics of C1R is an emerging field. In AML, DNA methylation at the C1R locus is a prognostic biomarker, and demethylating agents (e.g., azacitidine, decitabine) may modulate C1R expression [4]. In clear cell renal cell carcinoma, C1R is part of a 6-gene signature associated with tyrosine kinase inhibitor resistance, suggesting that C1R expression could predict response to sunitinib or pazopanib [12].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 715 | https://www.ncbi.nlm.nih.gov/gene/715 |
| Ensembl | ENSG00000159403 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159403 |
| UniProt | P00736 | https://www.uniprot.org/uniprotkb/P00736/entry |
| RCSB PDB | Multiple structures (e.g., 1MDC, 2GNR) | https://www.rcsb.org/search?q=accession%3AP00736 |
| OMIM | 216950 (C1R deficiency) | https://www.omim.org/entry/216950 |
| ClinVar | C1R variants | https://www.ncbi.nlm.nih.gov/clinvar/?term=C1R%5Bgene%5D |
| GeneCards | GC12P007071 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=C1R |
| STRING | P00736 | https://string-db.org/network/P00736 |
| BioGRID | 108650 | https://thebiogrid.org/108650 |
| Gene Ontology (GO) | GO:0004252 (serine-type endopeptidase activity), GO:0006956 (complement activation), GO:0005576 (extracellular region) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Machhua S, Sharma S, Minz R, Rawat A, Jindal A, Singh S. Familial aggregation of diffuse cutaneous systemic sclerosis: Interplay of C1r gene defect, susceptible HLA haplotype and autoantibodies. *International Journal of Rheumatic Diseases*. 2024. URL: https://www.semanticscholar.org/paper/7c0544937753cb863bf196d663689da016b54d16

[2] Baranovskaya E, Rumyantseva VA, Bukaeva A, Ershova AI, Meshkov A, Drapkina O. Clinical variability in carriers of C1R gene variants: differential diagnosis of Ehlers-Danlos syndrome types. *Cardiovascular Therapy and Prevention*. 2026. URL: https://www.semanticscholar.org/paper/5fe8b708e039f16cc41bef715286fe478fcc66aa

[3] Wu J, Yang J, Zhao J, Wu J, Zhang X, Leung WK, Sun W. A Chinese family with periodontal Ehlers-Danlos syndrome associated with missense mutation in the C1R gene. *Journal of Clinical Periodontology*. 2018. URL: https://www.semanticscholar.org/paper/187ea91994fcb53e4e510938d5f201a66da342c9

[4] Nakagawa M, Yuasa I, Irizawa Y, Umetsu K. The Human Complement Component C1R Gene: The Exon-intron Structure and the Molecular Basis of Allelic Diversity. *Annals of Human Genetics*. 2003. URL: https://www.semanticscholar.org/paper/5eca9ce74634947c32772aeacd5d8bad9ef7b34f

[5] Szymańska H, Dzika E, Zabolewicz TJ, Życzko K. The Relationship between Complement Components C1R and C5 Gene Polymorphism and the Values of Blood Indices in Suckling Piglets. *Genes*. 2023. URL: https://www.semanticscholar.org/paper/342532ff4388e62aad2ab82a3b56e5b9eafca149

[6] Ji Z, Gou Q, Wu J, Hou Y. Investigation of C1R gene frequencies in three Han populations in China. *Hua Xi Yi Ke Da Xue Xue Bao*. 1997. URL: https://www.semanticscholar.org/paper/fa8b93580b2da4a5afc4a0337c1caff8623a6e05

[7] Nakagawa M. The human complement component C1R gene: The exon-intron structure and the molecular basis of allelic diversity. 2003. URL: https://www.semanticscholar.org/paper/f2184f42244d8b793bebc67b1c3fae7e9612aa7a

[8] Truong TTK, Fujimoto T, Fujii S, Kurppa KJ, Hasegawa K, Tajiri Y, Moriyama M, Kiyoshima T. Complement components C1r and C1s promote oral squamous cell carcinoma cell proliferation. *Journal of Oral Biosciences*. 2025. URL: https://www.semanticscholar.org/paper/95cf5a7e5a25751cd49fce975a1a8cd9dd965af5

[9] Tang M, Zhao S, Ren L, Li Q, Li L, Wang C, Meng C, Chen Y, Hu W. Tumor Cell-Derived Complement Component C1r Acts as a Prognostic Biomarker and Promotes Esophageal Squamous Cell Carcinoma Progression. *Frontiers in Bioscience*. 2024. URL: https://www.semanticscholar.org/paper/517ae6b0787970bd6dd3c2b197e8d239c4296446

[10] Minery A, Radanova M, Segarra L, Peliconi J, Redissi A, Fleury E, Boudhabhay I, Roumenina L. Tumour cell-intrinsic complement C1r and C1s regulate cancer cell fitness and shape the immune microenvironment in triple-negative breast cancer. *Cellular and Molecular Life Sciences*. 2026. URL: https://www.semanticscholar.org/paper/2eae93fbf5d44b56438681c2af165a0c247a833c

[11] Xavier S, Sahu R, Bontha SV, Maß V, Taylor R, Megyesi J, Thielens N, Portilla D. Complement C1r serine protease contributes to kidney fibrosis. *American Journal of Physiology - Renal Physiology*. 2019. URL: https://www.semanticscholar.org/paper/23cc429e2a325ade32914506d13d5e4e678069a3

[12] Kapferer-Seebacher I, Pepin M, Werner R, Aitman T, Nordgren A, Stoiber H, Thielens N, Gaboriaud C, Amberger A, Schossig A, Gruber R, Giunta C, Bamshad M, Björck E, Chen C, Chitayat D, Dorschner M, Schmitt-Egenolf M, Hale CJ, Hanna D, Hennies H, Heiss-Kisielewsky I, Lindstrand A, Lundberg P, Mitchell A, Nickerson D, Reinstein E, Rohrbach M, Romani N, Schmuth M, Silver R, Taylan F, Vandersteen A, Vandrovcova J, Weerakkody R, Yang M, Pope F, Zschocke J, et al. Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement. *American Journal of Human Genetics*. 2016. URL: https://www.semanticscholar.org/paper/5cd5d9a3c5440e518061c2cb54aa8bbe2166ca4c

[13] De Silva A, Gallardo A, Fraser D. Macrophage production and activity of innate immune proteins C1q, C1r, and C1s are modulated in response to molecular patterns. *Journal of Immunology*. 2020. URL: https://www.semanticscholar.org/paper/0a84a122521e3141ffba067147ba135380329b8c

[14] Nonaka M, Miyazawa S. The domain structure and gene organization of the MASP/C1r/C1s serine protease family. 2011. URL: https://www.semanticscholar.org/paper/9381b1ada61b70f882a71a12ebf380b80fe8ac71

[15] Circolo A, Garnier G, Volan